6-Shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection

Graduate School of East-West Medical Science, Kyung Hee University Global Campus, #1732 Deogyeong-daero, Giheung-gu, Yongin, Gyeonggi-do 446-701, Republic of Korea.
Neuropharmacology (Impact Factor: 4.82). 03/2012; 63(2):211-23. DOI: 10.1016/j.neuropharm.2012.03.016
Source: PubMed

ABSTRACT Inflammatory processes in the central nervous system play an important role in a number of neurodegenerative diseases mediated by microglial activation, which results in neuronal cell death. Microglia act in immune surveillance and host defense while resting. When activated, they can be deleterious to neurons, even resulting in neurodegeneration. Therefore, the inhibition of microglial activation is considered a useful strategy in searching for neuroprotective agents. In this study, we investigated the effects of 6-shogaol, a pungent agent from Zingiber officinale Roscoe, on microglia activation in BV-2 and primary microglial cell cultures. 6-Shogaol significantly inhibited the release of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) induced by lipopolysaccharide (LPS). The effect was better than that of 6-gingerol, wogonin, or N-monomethyl-l-arginine, agents previously reported to inhibit nitric oxide. 6-Shogaol exerted its anti-inflammatory effects by inhibiting the production of prostaglandin E(2) (PGE(2)) and proinflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and by downregulating cyclooxygenase-2 (COX-2), p38 mitogen-activated protein kinase (MAPK), and nuclear factor kappa B (NF-κB) expression. In addition, 6-shogaol suppressed the microglial activation induced by LPS both in primary cortical neuron-glia culture and in an in vivo neuroinflammatory model. Moreover, 6-shogaol showed significant neuroprotective effects in vivo in transient global ischemia via the inhibition of microglia. These results suggest that 6-shogaol is an effective therapeutic agent for treating neurodegenerative diseases.

Download full-text


Available from: Dong Hyun Kim, Dec 26, 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The resort worldwide to edible medicinal plants for medical care has increased significantly during the last few years. Currently, there is a renewed interest in the search for new phytochemicals that could be developed as useful anti-inflammatory and anti-allergic agents to reduce the risk of many diseases. The activation of nuclear transcription factor-kappa B (NF-κB) has now been linked to a variety of inflammatory diseases, while data from numerous studies underline the importance of phytochemicals in inhibiting the pathway that activates this transcription factor. Moreover, the incidence of type I allergic disorders has been increasing worldwide, particularly, the hypersensitivity to food. Thus, a good number of plant products with anti-inflammatory and anti-allergic activity have been documented, but very few of these compounds have reached clinical use and there is scant scientific evidence that could explain their mode of action. Therefore, this paper intends to review the most salient recent reports on the anti-inflammatory and anti-allergic properties of phytochemicals and the molecular mechanisms underlying these properties.
    Molecules 01/2012; 18(1):322-53. DOI:10.3390/molecules18010322 · 2.42 Impact Factor
  • Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 10/2012; DOI:10.1016/j.fct.2012.10.019 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The functional roles of transient receptor potential (TRP) channels in the gastrointestinal tract have garnered considerable attention in recent years. We previously reported that daikenchuto (TU-100), a traditional Japanese herbal medicine, increased intestinal blood flow (IBF) via adrenomedullin (ADM) release from intestinal epithelial (IE) cells. TU-100 contains multiple TRP activators. In the present study, therefore, we examined the involvement of TRP channels in ADM-mediated vasodilatatory effect of TU-100. Rats were treated intraduodenally with a TRPV1 agonist capsaicin (CAP), a TRPA1 agonist allyl-isothiocyanate (AITC), or TU-100 and jejunum IBF was evaluated using a laser Doppler blood flowmetry. All 3 compounds resulted in vasodilatation, and the vasodilatory effect of TU-100 was abolished by a TRPA1-antagonist but not by a TRPV1-antagonist. Vasodilatation induced by AITC and TU-100 was abrogated by anti-ADM antibody treatment. RT-PCR and flow cytometry revealed that an IEC-6 cell line originated from the small intestine and purified IE cells expressed ADM and TRPA1 but not TRPV1. AITC increased ADM release in IEC cells remarkably, while CAP had no effect. TU-100 and its ingredient [6]-shogaol (6SG) increased ADM release dose-dependently and the effects were abrogated by TRPA1-antagonist. 6SG showed similar TRPA1-dependent vasodilatation in vivo. These results indicate that TRPA1 in IE cells may play an important role in controlling bowel microcirculation via ADM release. Epithelial TRPA1 appears to be a promising target for the development of novel strategies for the treatment of various gastrointestinal disorders.
    AJP Gastrointestinal and Liver Physiology 12/2012; DOI:10.1152/ajpgi.00356.2012 · 3.74 Impact Factor